Skip to main content
Premium Trial:

Request an Annual Quote

Hybridon Granted Patent on Circular Oligonucleotides For Antisense

NEW YORK, May 20-The antisense chemistry company Hybridon said today that it has been issued a U.S. patent for its class of novel circular oligonucleotides.


These oligonucleotides are designed so that a functional domain and a protective domain are linked together in a circular structure. As the functional domain binds to its target mRNA, the circular structure opens to inhibit target protein expression.


According to Hybridon, this structure improves stability and decreases non-specific interactions.


This second-generation technology is being developed for a range of antisense applications, including target validation, antinses drugs and diagnostic probes.


Hybridon's patent was issued by the U.S. Patent and Trade Office on May 7.

The Scan

Sick Newborns Selected for WGS With Automated Pipeline

Researchers successfully prioritized infants with potential Mendelian conditions for whole-genome sequencing or rapid whole-genome sequencing, as they report in Genome Medicine.

Acne-Linked Loci Found Through GWAS Meta-Analysis

Researchers in the European Journal of Human Genetics find new and known acne vulgaris risk loci with a genome-wide association study and meta-analysis, highlighting hair follicle- and metabolic disease-related genes.

Retina Cell Loss Reversed by Prime Editing in Mouse Model of Retinitis Pigmentosa

A team from China turns to prime editing to correct a retinitis pigmentosa-causing mutation in the PDE6b gene in a mouse model of the progressive photoreceptor loss condition in the Journal of Experimental Medicine.

CRISPR Screens Reveal Heart Attack-Linked Gene

Researchers in PLOS Genetics have used CRISPR screens to home in on variants associated with coronary artery disease that affect vascular endothelial function.